Author of

• 14306

  +

  P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14309

    +

    P2.01-003 - T-Cytotoxic Specific Immunotherapy in NSCLC with Brain Metastases NCT00104780 (ID 1202)

    09:30 - 09:30  |  Author(s): F. Nugent
    • Abstract
    • Slides

    Background:
    Brain metastases (BM) come with poor prognosis (median survival 3 to 6 months) and data are lacking as patients are often excluded from clinical trials.
    
    Methods:
    We present the results of a subgroup of NSCLC patients with BM treated with OSE-2101 (T-cytotoxic specific immunotherapy combining 9 epitopes targeting 5 tumor associated antigens and 1 pan-DR epitope) during a phase IIb study of OSE-2101 (1 injection per 3 week for 6 injections followed by 1 injection every 2 to 3 months) in advanced stage IIIB and IV NSCLC (Barve et al. 2008. J Clin Oncol 26:4418-4425). Patients were eligible whatever the number of prior chemotherapy (chemo) lines (65.5% entering 3rd line) and patients with stable BM for 2 months could be included. Six out of 64 treated patients had BM prior to inclusion and are reviewed.
    
    Results:
    

    Table 1: NSCLC patients included with BM

    Patient	108	150	169	132	133	135
    Gender	F	M	M	M	M	M
    Ethnic origin	CAU	CAU	CAU	CAU	AA	CAU
    Age (years)	46	61	58	79	46	57
    ECOG performance status	1	1	1	1	1	1
    Previous treatment	RT 30 Gy Chemo 2 lines	WBRT 30 Gy Chemo 2 lines	RT 30 Gy Chemo 2 lines	WBRT 30 Gy Chemo 3 lines	RT 30 Gy Chemo 1 line	WBRT 30 Gy Chemo 3 lines

    AA: African-American, CAU: Caucasian, Chemo: chemotherapy, F: female, Gy: Gray, M: male, RT: radiotherapy, WBRT: whole brain radiotherapy Table 2: Response to therapy

    Patient	108	150	169	132	133	135
    OS	30.16 mo	41 mo*	16.5 mo	9.6 mo	11 mo	7 mo**
    Time without progression	11.57 mo	24.39 mo	11.9 mo	4.53 mo	6.2 mo	2 mo*[2]
    CTL response (positive epitopes out of 5 tested)	3	2	5	2	1	Not tested
    HTL response	+	+	+	-	-	Not tested

    * Patient still alive at the time of the last follow up, ** treatment stopped after 2 injections for progressive disease. CTL: cytotoxic T lymphocytes, HTL: helper T lymphocytes, mo: months, OS: Overall survival, The 6 BM patients present long survival (median 13 mo, range 7-41) considering the advanced stage and the poor prognosis of these heavily pretreated patients. All patients had received from 1 to 3 previous chemo lines. Evaluation of CTL responses to 5 epitopes of OSE-2101 in 5 patients shows that each patient had a CTL response to at least one and up to 5 epitopes. Surprisingly patients with positive HTL response (patient 108, 150, 169) achieve the longest OS when compared with negative HTL patients (132 and 133).
    
    Conclusion:
    Long OS has been documented in NSCLC patients with BM treated with T-specific immunotherapy following RT and 1 to 3 previous chemo lines.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.